Syros Pharmaceuticals Announces Strategic Business Restructuring and Clinical Trial Developments
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), based in Cambridge, Massachusetts, continues to pioneer advancements in the field of hematologic malignancies. Today, the company has made significant announcements regarding its future trajectory and ongoing clinical research endeavors, highlighting its strategy to streamline operations while advancing medical research.
Following a strategic decision, Syros Pharmaceuticals has revealed its intention to voluntarily delist its common stock from the Nasdaq Stock Market. Additionally, it will deregister its common stock to suspend reporting obligations under the Securities and Exchange Act of 1934. This move has been endorsed by the company s Board of Directors and reflects an effort to refocus resources and optimize operational efficiencies.
Moreover, Syros is making critical adjustments in its clinical trial portfolio. The company announced its decision to cease enrollment in the SELECT-AML-1 Phase 2 clinical trial. This study was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine, compared to a doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute forms of hematologic malignancies. The focus on optimizing patient outcomes and advancing new standards of care continues to guide Syros’ research and development initiatives.
In addition to these strategic developments, Syros is gearing up for its upcoming financial announcement. The company will report its second quarter 2024 financial results on July 31, 2024, at 8:30 a.m. ET. This live conference call and webcast will also provide a business update, offering stakeholders insights into the company s financial health and strategic direction. Participants can access the conference call by dialing toll-free numbers provided for domestic and international callers.
These pivotal decisions underscore Syros Pharmaceuticals’ commitment to its mission of transforming the standard of care for hematologic malignancies, while thoughtfully managing its resources to strengthen its scientific and financial standing. As the company navigates these changes, it remains steadfast in its resolution to innovate and deliver novel therapeutic solutions for patients.
Comments